Anyanda Pharmaceutical Technology

Anyanda Pharmaceutical Technology (also known as InflamaX Pharmaceuticals) is a clinical-stage biotechnology company founded in 2022 and headquartered in Guangzhou, China, with additional operations in St. Louis, Missouri. The company focuses on developing innovative small molecule therapeutics that target the tissue microenvironment to treat immune-inflammatory diseases, cancer, pain, neurological disorders, and osteoarthritis. Its lead clinical candidate, MAX-001, is a next-generation, highly selective COX-2 inhibitor designed to reduce prostaglandin E2 (PGE2) levels in the tumor microenvironment, thereby restoring immune function and overcoming resistance to immune checkpoint inhibitors. Anyanda is currently advancing MAX-001 in Phase 1 clinical trials in China and Australia for the treatment of advanced refractory solid tumors.